In 90% of people with erythropoietic protoporphyria (EPP), the disease results from the inheritance of a common hypomorphic FECH allele, encoding ferrochelatase, in trans to a private deleterious FECH mutation. The activity of the resulting FECH enzyme falls below the critical threshold of 35%, leading to the accumulation of free protoporphyrin IX (PPIX) in bone marrow erythroblasts and in red cells. The mechanism of low expression involves a biallelic polymorphism (c.315À48T>C) localized in intron 3. The 315À48C allele increases usage of the 3 0 cryptic splice site between exons 3 and 4, resulting in the transcription of an unstable mRNA with a premature stop codon, reducing the abundance of wild-type FECH mRNA, and finally reducing FECH activity. Through a candidate-sequence approach and an antisense-oligonucleotide-tiling method, we identified a sequence that, when targeted by an antisense oligonucleotide (ASO-V1), prevented usage of the cryptic splice site. In lymphoblastoid cell lines derived from symptomatic EPP subjects, transfection of ASO-V1 reduced the usage of the cryptic splice site and efficiently redirected the splicing of intron 3 toward the physiological acceptor site, thereby increasing the amount of functional FECH mRNA. Moreover, the administration of ASO-V1 into developing human erythroblasts from an overtly EPP subject markedly increased the production of WT FECH mRNA and reduced the accumulation of PPIX to a level similar to that measured in asymptomatic EPP subjects. Thus, EPP is a paradigmatic Mendelian disease in which the in vivo correction of a common single splicing defect would improve the condition of most affected individuals.
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Erythropoietic protoporphyria (EPP, MIM 177000) is a rare inherited disorder caused by the partial mitochondrial deficiency of ferrochelatase (FECH, EC 4.99.1.1.), the last enzyme in the heme biosynthesis pathway 1 (See also Balwani et al., 2012 in GeneReviews in the Web Resources). FECH is an inner mitochondrial membrane enzyme that catalyzes the insertion of ferrous iron into free protoporphyrin IX (PPIX) to form heme. FECH deficiency in medullar erythroid cells leads to overproduction and accumulation of photoactive PPIX in erythrocytes and subsequently in the plasma, skin, bile, and feces. 1 The most common clinical manifestation of the disease is lifelong acute photosensitivity of sun-exposed areas that first appears in early childhood. Although it is generally a benign disease, hepatic complications such as cholelithiasis or, in about 2% of cases, cirrhosis with rapidly fatal liver disease, can occur. [2] [3] [4] Cases of EPP have been reported in Europe, the USA, China, and Japan. So far, no case of EPP has been reported in individuals of African descent. Constitutively, FECH undergoes alternative splicing of exon 4 as a result of partial utilization of a cryptic intron 3 acceptor splice site located 63 bp upstream of the major intron 3/exon 4 boundary, resulting in the pseudo-exon inclusion of 63 nucleotides of intron 3 about 20% of the time. The aberrant mRNA contains an in-frame premature stop codon ( Figure 1 ) and is degraded by nonsense-mediated mRNA decay. [5] [6] [7] The hypomorphic C allele of a common intronic SNP, c.315À48T>C (rs2272783, Figure 1 ), is responsible for increasing the usage of the À63 bp cryptic intron 3 acceptor splice site from 20% (for the T allele) to 60% (for the C allele), resulting in a reduction of FECH activity. When, in combination with a severe FECH mutation on the other allele, the overall FECH activity falls below a critical threshold of about 35% of normal, PPIX accumulates, and photosensitivity occurs. 8, 9 Several studies in the USA, Europe, and Asia have confirmed that this mechanism is generally operative in EPP. [10] [11] [12] [13] [14] [15] According to the French Centre of Porphyria database, 94% of French EPP subjects show this striking inheritance pattern. Because EPP is primarily a seasonal disease, and because affected individuals present mainly non-life-threatening, dermatological symptoms, integrative gene therapy is not appropriate. Rather, correcting this single common splicing mutation by antisense oligonucleotide (ASO) therapy is an attractive strategy that should improve the condition of the majority of EPP subjects independently of the nature of their FECH mutation. ASOs, which are generally used for inhibiting gene expression, can also be used for modulating pre-mRNA splicing by targeting splice sites or by targeting positive or negative elements that affect splice-site selection. 16 In this study, we applied two strategies to identify ASOs that repress the partial inclusion of intron 3 in FECH mRNA: first, an ASO-tiling method to search for regulating cis-acting elements residing within the 130 bp stretch upstream of exon 4; and second, an orientated strategy in which we used three ASOs targeting the putative 315À48C-activated cryptic branch point, the cryptic acceptor splice site, or both the cryptic splice site and the 315À48C nucleotide ( Figure 2A and Table 1 ). For all of these experiments, we used locked nucleic acids (LNAs) that demonstrate nuclease resistance and enhance affinity for hybridization to complementary RNA. 17 This class of ASOs is highly effective for modifying pre-mRNA splicing patterns. 18 To investigate the effects of individual ASOs on splicing, we constructed two FECH minigenes (FECH-C-pcDNA3 and FECH-T-pcDNA3) comprising exon 3 (121 bp), a shortened intron 3 (300 bp, with either the c.315À48C or the c.315À48T genotype) and exon 4 (193 bp). We transfected these into Cos7 cells by using lipofectamine reagent (Invitrogen). Two days after transfection, we analyzed exon 3-4 FECH mRNA by RT-PCR with a pair of human primers (Table S1 ). These primers did not amplify the endogenous Cos7 FECH transcript ( Figure 2B ). The extent of intron 3 inclusion was expressed as the ratio of the intensity of the aberrantly spliced band to the sum of the intensities of the aberrantly and correctly spliced bands. FECH minigene transfection in Cos7 cells recapitulated the splicing pattern as shown in lymphoblastoid cell lines (LBCL) of 315À48C/C or T/T subjects. 7 The FECH-C-pcDNA3 minigene revealed a ratio of about 60%, and the FECH-T-pcDNA3 minigene one of 20% ( Figure 2B ). For the ASO-tiling experiments, we cotransfected the FECH-C-pcDNA3 minigene individually with each of the ASOs ( Figure S1A and Table S2 ; 13 ASOs, overlapping by 5 nt). None of the 13 LNA-ASOs used in the initial ''walk'' along intron 3 reduced intron 3 retention ( Figure S1B ). Only the ASO targeting position À45 to -63 (V1-LNA-ASO), which was obtained via the orientated strategy and was complementary to a sequence including the 315À48 polymorphism and the 3 0 cryptic acceptor splice site, reduced intron 3 inclusion to about 20% of the total RNA, a level similar to the level obtained with the FECH-T-pcDNA3 construction ( Figure 2B ). A doseresponse effect was already evident at 50 nM ASO concentration,and was maximal at 125 nM ( Figure 2B ). To further refine the targeting sequence, we microwalked around the À45 position by using 18 additional 15-mer LNAASOs ( Figure S2A and Table S2 ). Again, none displayed any effect, demonstrating that both the 315À48 region and the À63 acceptor splice site have to be targeted to achieve the repression of intron 3 inclusion ( Figure S2B and S2C). Finally, we tested whether the splicing was sensitive to the length of the ASO. We used eight additional Three hours later, the cells were transfected with 50, 125, or 250 nM LNA and 2 ml of Lipofectamine 2000. Emetin (Sigma Aldrich) was added simultaneously in the medium at a final concentration of 30 mM. Twenty-four hours later, the cells were harvested, and total RNA was extracted via the RNAplus reagent (MP Biomedical). Human-specific exon 3-4 FECH primers were used for qualitative PCR that amplified the correctly and aberrantly spliced mRNA, the PCR products were analyzed by electrophoresis on a 3% agarose gel, and the density of the PCR bands was measured with Image J Software. The migration positions of the normal exon 3-4 81 bp amplimer and the aberrantly spliced 144 bp product are indicated on the right. Ratios of the aberrantly spliced RNA to the total RNA are indicated at the bottom.
LNA-ASOs, which were one or two bases longer than V1-LNA-ASO at either one or both extremities ( Figure S2D and Table S2 ). All these LNA-ASOs reduced intron 3 inclusion, but none was more effective than the V1-LNA-ASO ( Figure S2E ).
We further investigated whether reduction of intron 3 retention could also induce excess FECH mRNA production. Therefore, we measured FECH splicing in lymphoblastoid cell lines (LBCL) of an overt EPP-subject (subject II1, FECH genotype c.709delT mutation/315À48C) and her asymptomatic brother (subject II3, FECH genotype c.709delT mutation/315À48T, Figure 3A ). The optimal concentration (125 nM) of V1-LNA-ASO or mock-ASO (a complementary sequence of the ASO À45 to -63: 5 0 -AAAA CATTTCTCAGGCTGC-3 0 ) were transfected with lipofectamine reagent. Three hours after transfection, emetine (Sigma-Aldrich) was added to the medium to block NMD. Forty-eight hours after ASO transfection, endogenous exon 3-4 splicing was analyzed with exon 3-4 RT-PCR (Table 1 ; Figure 3B ). As expected, intron 3 retention in the LBCL of subject II3 (transfected with the mock ASO) was about 25% lower than in the LBCL of subject II1 (abnormal mRNA/total mRNA ratio 0.30 versus 0.38, p ¼ 0.0022; Figure 3B ). Interestingly, when the LBCL of subject II1 was transfected with V1-LNA-ASO, the proportion of abnormally spliced RNA decreased from 0.38 to a level similar to that measured in the asymptomatic II3 subject (0.32 versus 0.30, not significant; Figure 3B ). Wild-type FECH mRNA was then measured by RT-qPCR using primers specific to the wild-type exon 3-4 boundary (Table S1 ). Twenty-four hours after transfection, normal FECH mRNA was 30% more abundant in the LBCLs of the asymptomatic (II3) than the overt (II1) subject ( Figure 3C ), 7 and 24 hr later, the normal mRNA of the cells of the overt II1 subject treated with the V1-LNA-ASO was 1.8-and 1.7-fold higher than that of the II1 mock-transfected and II3 -V1-LNA-ASO-transfected cells, respectively ( Figure 3C ). In summary, we identified a sequence at nucleotides À45 to À63 that, when targeted by V1-LNA-ASO, reduced intron 3 inclusion in LBCL with a 315À48T/C genotype to a level comparable to that of the 315À48T/T genotype and increased wild-type mRNA production in the cells of an overt subject to a higher level than that measured in an asymptomatic EPP subject. Taken together, these results suggest that the V1-LNA-ASO has considerable therapeutic potential. The sequence at position À45 to À63 is intronic with regard to physiological exon 3-4 splicing, but it becomes exonic when the À63 cryptic splice site is used. The mechanisms underlying splicing redirection from the exon 3-4 boundary of the cryptic to the physiological exon are complex and not yet fully understood. Blocking exclusively either the 3 0 aberrant splice site (six ASOs: À50 to À64, À51 to À65, À52 to À66, À53 to À67, À61 to À75, and À54 to À74) or the 315À48 region (11 ASOs: À34 to À48, À35 to À49, À36 to À50, À37 to À51, À38 to À52, À39 to À53, À41 to À55, À45 to À59, À46 to À60, À47 to À61, and À48 toÀ62) was not sufficient to restore proper splicing. In the competition between the cryptic and the physiological splice sites, redirection of splicing toward the physiological site has to include blocking both the cryptic splice site and the 315À48 region, suggesting that this region might include an exonic splicing enhancer (ESE) of cryptic splicing or an intronic splicing inhibitor (ISI) of exon 3-4 splicing.
Because medullar erythroblasts are the relevant tissue to be therapeutically targeted in EPP, we tested the V1-ASO in differentiating CD34 þ -derived, erythroid progenitors isolated from the peripheral whole blood from two overt EPP subjects (A and B), one asymptomatic subject (D), and one control subject (C, Table 2 ). Our study was conducted in accordance with the World Medical Association Declaration of Helsinki ethical principles for medical research involving human subjects and its subsequent amendments. All subjects gave informed consent before undergoing investigation. Overt subjects A and B had a classical history of skin photosensitivity that began during childhood, a high level of erythrocyte-free protoporphyrin, and 25%-30% residual FECH activity in peripheral blood mononuclear cells. The FECH genotypes of the overt subjects consisted of a deleterious FECH mutation in trans to the hypomorphic 315À48C allele ( Table 2 ). The nonsense mutation of subject A most likely triggered mRNA degradation, and the mutation in subject B resulted in aberrant exon 10 splicing that conserved the correct reading frame. The third subject (subject D) was an asymptomatic EPP, and her FECH genotype consisted of a deleterious FECH nonsense mutation in trans to the 315À48T allele. Her erythrocyte PPIX levels were slightly above the normal limit (X2), and her FECH activity in peripheral blood mononuclear cells was~50% below normal (Table 2) .
For the oligonucleotide treatment, liposomal transfections of V1-LNA-ASO were ineffective because of their high toxicity and poor transfection efficiency (data not shown). We therefore used a free-uptake method in which morpholino-ASOs were added directly to the culture medium at a final concentration of 45 mM (see GeneReviews in Web Resources).
19,20 R. Kole and colleagues developed the original method to direct morpholino-ASOs to erythroid precursors in order to restore human beta-globin gene expression in human IVS2-654 thalassemic erythroid cells. 20 The authors also showed that adding labeled morpholinos to the culture medium from days 8 to 17 resulted in strong nuclear staining. The morpholinos were prepared and purified by Gene Tools, LLC (Philomath, USA). Two morpholino-ASOs, targeting the sequence at position À45 to À63 in either the antisense (PMO-V1) or the complementary sequence, respectively, were used for the control mock oligonucleotide (PMOmock). The oligonucleotides were labeled with fluorescein isithiocyanate (FITC). The phenotype differentiation of erythroid cells was monitored by flow cytometry (FACS Canto II, BD Biosciences). Cells were stained with the relevant isotype or antibodies (CD34PE 1/100 (A07776), CD36-FITC 1/100 (IM0766U), and CD71-FITC 1/100 (IM0483) from Beckman Coulter and GPA-PE 1/50 (MHGLA04) from Invitrogen). Hemoglobinization was monitored daily by benzidine staining. Cell morphology was established after May-Grünwald-Giemsa staining of cytospin preparations by light microscopy. Time-kinetic analysis of PPIX accumulation was determined by flow cytometry at four stages of differentiation: CFU (colony-forming unit) erythroblast (CFU E), pro-and intermediate-erythroblast (pro-E, int E), and late erythroblast (late E). These stages were established on the basis of cell morphology (MGG coloration; Figure S3 ) and the expression of the CD71 and GPA surface markers, which correspond with the major stages of development: CFU E (CD71 lo , GPA (Table S1 ).
To determine the optimal conditions for ASO treatments, we established a culture of CD34 þ cells isolated from a healthy control. We assayed the time course of FECH mRNA expression by RT-qPCR, and FECH mRNA increased dramatically from the CFU E stage to the late E stage (23-fold induction; Figure S4 ). Erythroid differentiation was confirmed on the basis of cell morphology ( Figure S3 ), FACS analyses, and the progressive appearance of hemoglobinized cells ranging from 0% at the CFU E stage to >95% at the late E stage. Finally, morpholino oligonucleotides were added before the induction of heme production at the CFU E stage (after~7 days in culture) and maintained at the same concentration (45 mM) until mature cells were obtained.
Normal FECH and ALAS2 mRNAs were quantified at the late E stage, when FECH mRNA expression was highest. At this stage of differentiation, the normal FECH mRNA in ASO-treated cells from subjects A and B had increased by 59% and 98%, respectively, in comparison with mocktreated cells (Table 3) . FECH mRNA in V1-treated cells of subject A remained 50% lower than in those of control subject C. This could have been due to the type of the mutations for subject A: a 1 bp deletion introducing a premature STOP codon potentially leading to a null allele. FECH expression could have been improved primarily because of the redirection of splicing but also because of an overall improvement in heme biosynthesis. Indeed, ALAS2, encoding the key regulator of erythroid heme biosynthesis, was overexpressed in V1-treated cells when compared with mock-treated cells at the same stage of differentiation (48% and 74% improvement for subjects A and B, respectively; Table 3 ), probably leading to increased ALAS2 activity. ALAS2 expression is also posttranscriptionally regulated by the IRE/IRP system, and in a situation where iron is normally available, we expect the ALAS2 mRNA translation not to be repressed. In the cells of EPP subjects who were treated with the V1 morpholino, we observed a cumulative reduction in the amount of PPIX as erythroid differentiation progressed and culminated at the late E end-point stage (44% and 58% reduction for subjects A and B, respectively; Figure 4) . Remarkably, PPIX accumulation decreased in the cultured progenitor cells of overt EPP subjects A and B to a level similar to that found in the asymptomatic subject D, although the amount of PPIX remained higher than in the normal subject C (Figure 4 ). This result was in agreement with the observation that the total amount of erythrocyte PPIX that was measured in peripheral RBCs from asymptomatic EPP subjects was Subjects A, B, C, and D are described in Table 2 . Abbreviations are as follows: M, deleterious FECH mutation; WT, wild-type FECH; T, 315À48T allele; and C, 315À48C allele. Total RNA was extracted at the late E stage, and morpholino-ASO targeting position À45 to À63 or mock morpholino-ASO was added seven days after the CD34 þ cells were isolated from whole blood. ALAS2 and WT FECH RNA were analyzed by RT-qPCR with primers specific to the normal exon 3-4 spliced RNA of FECH. Both quantifications were normalized to two genes (B2M [MIM 109700] and HPRT1 [MIM 308000]), and the results are expressed as a percentage from the mock condition of subject C. þ cells were cultured in Iscove Dulbecco's modified Eagle medium (Invitrogen) containing 15% BIT 9500 (StemCell Technologies), 100 ng/ml stem cell factor, 2 U/ml erythropoietin, 10 ng/ml interleukin-6, and 10 ng/ml interleukin-3 (all cytokines were from Miltenyi Biotec). Morpholino oligonucleotides were added before the induction of heme production at the CFU E stage (after~7 days in culture) and maintained at the same concentration (45 mM) until mature cells were obtained. Time kinetic analysis of PPIX accumulation was determined by flow cytometry at four stages of differentiation: CFU E, pro E, int E, and late E, and graphs represent the ratios between the mean fluorescence intensity (MFI) values of the accumulated PPIX to MFI of FITC-positive cells in erythroid cells from two overt EPP subjects (subjects A and B), one healthy control subject (subject C), and one asymptomatic EPP subject (subject D), who were each treated with PMO-V1 (triangles) or PMO-mock (squares).
2.5-fold higher than in healthy subjects; however, this value remained at subclinical levels ( Figure 5) . It is thus possible that the reduced amount of PPIX observed in erythroid cells of affected individuals could become sufficiently low to suppress skin sensitivity in vivo.
Our study is a proof-of-concept for the ability of ASO therapy to restore normal exon 3-4 pre-mRNA splicing and increase normal FECH mRNA production while decreasing PPIX accumulation to a subclinical level in cultured erythropoietic cells from EPP subjects, and it opens a new field in treating EPP. The correction of FECH exon 3-4 splicing is an attractive therapeutic approach for EPP because the 315-48C allele is present in more than 90% of overt EPP subjects. Moreover, a modest increase in FECH activity is sufficient to shift the subject's status from overt to asymptomatic. 8 In contrast to integrative gene therapy, antisense therapy has several advantages.
(1) Because the correction occurs in medullar erythroblasts and persists in circulating erythrocytes with a lifespan of about 120 days, the effects of the oligonucleotide treatment are probably prolonged; (2) the splicing correction occurs in the endogenous gene that is transcribed in its physiological environment, thus preventing excessive or inappropriate expression; and (3) a pharmacological treatment is easier to administer than somatic gene therapy and can easily be interrupted in the case of adverse effects. Targeting pre-mRNA splicing as a therapeutic strategy in Mendelian disorders was proposed several years ago for Duchenne muscular dystrophy, 21 spinal muscular atrophy 22 and b-thalassemia (MIM 613985). In 1993, Dominski et al. demonstrated that correct splicing can be restored in vitro by an ASO targeting the b-globin premRNA. 23 Two laboratories were later able to improve hemoglobin synthesis in vivo and to reduce cell damage in humanized IVS2-654 thalassemic mice by using either a morpholino oligomer conjugated to a peptide or an antisense RNA vector. 24, 25 The challenge facing antisense therapeutic strategies is to develop efficient ways to target ASO to specific cells, in our case to the erythroid progenitors. For systemic administration, it is important to enhance the specificity of the treatment while reducing the concentration of ASOs so as to limit toxicity.Different strategies, including cell-penetrating peptides, aptamers, and cationic liposome-ASO complexes, have aimed to enhance ASO targeting. For erythropoietic protoporphyria therapy, an interesting target could be transferrin receptor 1 (CD71), which is expressed at a very high level during the differentiation stage, when FECH incorporates iron into PPIX to form heme. Several peptides and aptamers that bind with high affinity to human CD71 and display endocytotic properties are already available, 26, 27 suggesting that this or similar compounds should be tested in a humanized mouse model of EPP and that it might subsequently hold promise in the treatment of individuals with EPP.
Supplemental Data
The Supplemental Data include four figures and two tables and can be found with this article online at http://www.cell.com/ajhg. Figure 5 . Erythrocyte Protoporphyrin IX in 40 EPP-Affected Families Total erythrocyte PPIX was measured in 40 EPP-affected families, each having one overt EPP subject, one asymptomatic EPP subject, and one healthy subject. The results were expressed as a histogram showing the mean and standard deviation. Means were compared with the ''t'' test with Prism 4. Total erythrocyte PPIX level was 2.5-fold higher in peripheral RBCs from asymptomatic EPP subjects than in healthy subjects.
